NDA and BLA submission news made up for a quiet week on the approvals front at the US Food and Drug Administration.
Infectious disease patients saw three recent submissions, all representing different technologies: Iterum Therapeutics Limited’s antibiotic sulopenem, Atox Bio’s...






